Latest Insider Transactions at Neuroone Medical Technologies Corp (NMTC)
This section provides a real-time view of insider transactions for Neuroone Medical Technologies Corp (NMTC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NEUROONE MEDICAL TECHNOLOGIES Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NEUROONE MEDICAL TECHNOLOGIES Corp's insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 31
2023
|
David A Rosa CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,239
-0.49%
|
$2,239
$1.61 P/Share
|
Mar 23
2023
|
Mark Christianson Business Development Director |
SELL
Open market or private sale
|
Direct |
12,711
-3.63%
|
$12,711
$1.5 P/Share
|
Mar 22
2023
|
Mark Christianson Business Development Director |
SELL
Open market or private sale
|
Direct |
11,667
-3.22%
|
$11,667
$1.51 P/Share
|
Mar 21
2023
|
Mark Christianson Business Development Director |
SELL
Open market or private sale
|
Direct |
2,122
-0.58%
|
$2,122
$1.6 P/Share
|
Mar 16
2023
|
Jeffrey S Mathiesen Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,576
+19.19%
|
-
|
Mar 16
2023
|
Paul Buckman Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,576
+20.21%
|
-
|
Mar 16
2023
|
Edward Andrle Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,576
+24.26%
|
-
|
Feb 03
2023
|
Steve Mertens Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,054
-14.5%
|
$6,054
$1.47 P/Share
|
Feb 03
2023
|
Mark Christianson Business Development Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,175
-0.59%
|
$2,175
$1.47 P/Share
|
Feb 03
2023
|
David A Rosa CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
53,750
-10.44%
|
$53,750
$1.47 P/Share
|
Jun 15
2022
|
Ronald W. Mc Clurg Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+12.99%
|
$10,000
$1.02 P/Share
|
Jun 10
2022
|
Ronald W. Mc Clurg Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
14,000
+19.72%
|
$14,000
$1.06 P/Share
|
May 31
2022
|
Edward Andrle Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,240
+40.12%
|
-
|
May 31
2022
|
Paul Buckman Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,240
+32.52%
|
-
|
May 31
2022
|
Jeffrey S Mathiesen Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,240
+30.68%
|
-
|
May 24
2022
|
Ronald W. Mc Clurg Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,500
+19.63%
|
$0
$0.98 P/Share
|
May 20
2022
|
Ronald W. Mc Clurg Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
17,500
+35.0%
|
$0
$0.85 P/Share
|
Feb 03
2022
|
Mark Christianson Business Development Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+3.94%
|
-
|
Feb 03
2022
|
Steve Mertens Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,750
+50.0%
|
-
|
Feb 03
2022
|
David A Rosa CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+32.7%
|
-
|
Feb 03
2022
|
Ronald W. Mc Clurg Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
Jun 24
2021
|
Mark Christianson Business Development Director |
SELL
Open market or private sale
|
Direct |
600
-0.06%
|
$3,600
$6.3 P/Share
|
Jun 23
2021
|
Mark Christianson Business Development Director |
SELL
Open market or private sale
|
Direct |
11,300
-1.04%
|
$67,800
$6.74 P/Share
|
Jun 02
2021
|
Edward Andrle Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,592
+24.17%
|
-
|
Jun 02
2021
|
Paul Buckman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,592
+12.75%
|
-
|
Jun 02
2021
|
Jeffrey S Mathiesen Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,592
+11.09%
|
-
|